Trending Now
Jaguar Health Inc. (NASDAQ:JAGX) Commences Phase 3 Of Crofelemer Study In...
Jaguar Health Inc. (NASDAQ:JAGX) has announced that its wholly-owned subsidiary, Napo Pharmaceuticals Inc., has commenced a vital third phase crofelemer (Mytesi®) study, The trial...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
CHF Solutions Inc (NASDAQ:CHFS) Strikes Distribution Agreement Deal With RenalSense For...
CHF Solutions Inc (NASDAQ:CHFS) announced earlier this month that it entered into a partnership deal that will allow it to provide real-time renal diagnostics...
MAKE IT MODERN
LATEST REVIEWS
Moleculin Biotech Inc. (NASDAQ: MBRX) Announces Preliminary Results Of Study Evaluating...
Moleculin Biotech Inc. (NASDAQ: MBRX) has announced interim findings from the company’s US phase 1/2 study following the completion of a safety review of...
MAKE IT MODERN
PERFORMANCE TRAINING
TOP Financial Group Limited ($TOP) surges over 600% after market hours
TOP Financial Group Limited (TOP), a leading financial services company, has seen a significant increase in its stock price in the latest...
Aytu Bioscience Inc (NASDAQ:AYTU) Reports An Impressive Fiscal Q4 2020 Performance
Aytu Bioscience Inc (NASDAQ:AYTU) recently released its financial report for its fiscal Q4 2020 ended June 30, 2020, revealing impressive financial highlights.
The company’s net...
Selector Biosciences Inc. (NASDAQ:SELB) And Sarepta Therapeutics Inc. (NASDAQ:SRPT) Sign Research Option And License...
Selector Biosciences Inc. (NASDAQ:SELB) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) have announced the signing of a Research Option and License Agreement. The agreement grants Sarepta...
Atossa Therapeutics Pleased After FDA Gives It A “Safe To Proceed” Letter To Continue...
Ovarian cancer is a life-threatening condition that continues to claim many lives worldwide. Atossa Therapeutics Inc has been developing wide-ranging products and solutions to help...
The GBT Foundation Announces the Submission of Applications for New Grants
The GBT foundation recently issued other organizations a chance to submit their applications for its latest sickle cell program. The program provides a call...
MAKE IT MODERN
